Diabetics worldwide 2021, 2030, and 2045
The number of diabetics worldwide in 2021 was 537 million. That number is expected to grow until at least the year 2045. The projected number of diabetics is expected to reach 783 million by that time. With an increased number of diabetics, the prevalence of diabetes is also projected to increase to around 12 percent by 2045.
Diabetes prevalence globally
Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2021. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. French Polynesia, followed by Mauritius, had the highest prevalence of diabetics worldwide as of 2021.
Diabetes pharmaceuticals
Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabete. The top drug for the treatment of diabetes, based on market share in 2017, was NovoRapid by Novo Nordisk. NovoRapid is a rapid-acting insulin marketed for both children and adults.
Diabetes prevalence globally
Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2021. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. French Polynesia, followed by Mauritius, had the highest prevalence of diabetics worldwide as of 2021.
Diabetes pharmaceuticals
Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabete. The top drug for the treatment of diabetes, based on market share in 2017, was NovoRapid by Novo Nordisk. NovoRapid is a rapid-acting insulin marketed for both children and adults.
